ATI RN
ATI Pharmacology
1. A client in an outpatient facility is taking Acarbose for type 2 Diabetes Mellitus. Which of the following laboratory tests should the nurse plan to monitor?
- A. WBC
- B. Serum potassium
- C. Platelet count
- D. Liver function test
Correct answer: D
Rationale: The correct answer is D: Liver function test. Acarbose, used for type 2 Diabetes Mellitus, can lead to liver toxicity with long-term use. Monitoring liver function tests periodically is crucial to detect any signs of liver dysfunction early and prevent complications. Choices A, B, and C are incorrect as Acarbose does not directly affect WBC, serum potassium, or platelet count levels.
2. A client has a new prescription for combination oral NRTIs for the treatment of HIV. Which of the following statements should the nurse include in discharge teaching?
- A. These medications work by inhibiting enzymes to prevent HIV replication.
- B. These medications work by preventing protein synthesis within the HIV cell.
- C. These medications work by weakening the cell wall of the HIV virus.
- D. These medications work by blocking HIV entry into cells.
Correct answer: A
Rationale: The correct answer is A. NRTI antiretroviral medications inhibit the enzyme reverse transcriptase, which is essential for HIV replication. By blocking this enzyme, the medications prevent the virus from replicating and spreading. This mechanism of action helps to control the progression of HIV infection in the body. Choices B, C, and D are incorrect because NRTIs do not work by preventing protein synthesis, weakening the cell wall of the virus, or blocking HIV entry into cells. These mechanisms are associated with different classes of antiretroviral medications used in HIV treatment.
3. A client is starting therapy with cisplatin, and a healthcare provider is providing education. Which of the following findings should the healthcare provider instruct the client to report?
- A. Tinnitus
- B. Nausea
- C. Constipation
- D. Weight gain
Correct answer: A
Rationale: The correct answer is A: Tinnitus. The healthcare provider should instruct the client to report tinnitus, as it can be an indication of ototoxicity, an adverse effect associated with cisplatin therapy. Ototoxicity is damage to the inner ear structures that can lead to hearing loss, making it crucial for the client to report any early signs such as tinnitus to prevent further complications. Choices B, C, and D are less concerning in the context of cisplatin therapy. Nausea and constipation are common side effects of cisplatin but are not typically indicative of serious complications requiring immediate reporting. Weight gain is not a typical side effect associated with cisplatin therapy and is less likely to be related to the medication.
4. A client has a new prescription for Metoclopramide. Which of the following instructions should the nurse include?
- A. Expect a rapid heart rate.
- B. Take the medication with meals.
- C. Report any signs of restlessness or involuntary movements.
- D. Avoid consuming dairy products.
Correct answer: C
Rationale: The correct instruction to include when teaching a client about Metoclopramide is to report any signs of restlessness or involuntary movements. Metoclopramide can lead to extrapyramidal symptoms, such as restlessness or involuntary movements. It is essential for clients to notify their healthcare provider if they experience these symptoms to receive appropriate management.
5. A healthcare provider is reviewing the health care record of a client who is asking about conjugated equine estrogens. The healthcare provider should inform the client this medication is contraindicated in which of the following conditions?
- A. Atrophic vaginitis
- B. Dysfunctional uterine bleeding
- C. Osteoporosis
- D. Thrombophlebitis
Correct answer: D
Rationale: Conjugated equine estrogens are contraindicated in individuals with a history of thrombophlebitis due to the increased risk of thrombotic events associated with estrogen use. Thrombophlebitis is a condition characterized by inflammation and blood clot formation in the veins, and estrogen therapy can exacerbate this condition, leading to serious complications such as deep vein thrombosis. Therefore, caution is advised when considering estrogen therapy in clients with a history of thrombophlebitis to prevent adverse outcomes. Choices A, B, and C are not contraindications for conjugated equine estrogens. Atrophic vaginitis and dysfunctional uterine bleeding may actually be conditions for which estrogen therapy is indicated. Osteoporosis can also be managed with estrogen therapy in certain cases to help prevent bone density loss.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access